On May 20, 2020 Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, reported that a total of six distinct abstracts on REBLOZYL (luspatercept-aamt) will be presented at the upcoming 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 (ASCO20) Virtual Scientific Program, held May 29-31, and at the 25th Annual European Hematology Association (EHA) (Free EHA Whitepaper) (EHA25) Virtual Congress, held June 11-21 (Press release, Acceleron Pharma, MAY 20, 2020, View Source [SID1234558338]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentations at ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program
Title: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients (Pts) With Lower-Risk myelodysplastic syndromes (MDS) with Ring Sideroblasts (RS) – Abstract: #7518
Session:
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Title: Clinical Benefit of Luspatercept in Patients (Pts) With Lower-Risk MDS (LR-MDS) and High Transfusion Burden in the Phase 3 MEDALIST Study – Abstract: #7554
Session:
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Poster presentations and poster discussions will be available on demand through the ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program beginning on May 29, 2020, at 8:00 a.m. EDT.
Presentations at EHA (Free EHA Whitepaper)25 Virtual Congress
Title: Assessment of Response to Luspatercept by β-Globin Genotype in Adult Patients With β-Thalassemia in the BELIEVE Trial – Abstract: Oral presentation S295
Title: Assessment of Longer-Term Efficacy and Safety in the Phase 3 BELIEVE Trial of Luspatercept to Treat Anemia in Patients (Pts) with β-Thalassemia – Abstract: e-Poster 1548
Title: Assessment of Dose-Dependent Response to Luspatercept in Patients (Pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) With Ring Sideroblasts in the Phase 3 MEDALIST Trial – Abstract: e-Poster 812
Title: Effects of Luspatercept on Serum Ferritin in Patients (Pts) With Lower-Risk Myelodysplastic Syndromes (MDS) With Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial – Abstract: e-Poster 807
Title: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients (Pts) With Lower-Risk myelodysplastic syndromes (MDS) with Ring Sideroblasts (RS) – Abstract: e-Poster 813
Title: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study – Abstract: e-Poster 798
All e-Poster and oral abstract presentations will be made available on the on-demand EHA (Free EHA Whitepaper)25 Virtual Congress Platform beginning on June 12, 2020 at 8:30 a.m. CEST.
About REBLOZYL (luspatercept-aamt)
REBLOZYL is the first and only U.S. Food and Drug Administration-approved erythroid maturation agent designed to promote red blood cell production through a novel mechanism. Luspatercept-aamt is being developed to treat anemia in patients with beta-thalassemia, MDS, and myelofibrosis. REBLOZYL is part of the global collaboration between Acceleron and Bristol Myers Squibb.